Trial finds that enoxaparin may be the preferred drug for initiating anticoagulation in atrial fibrillation*1Abstracted from: Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Circulation 2004; 109: 997-1003.

doi:10.1016/s1361-2611(04)00130-7

Trial finds that enoxaparin may be the preferred drug for initiating anticoagulation in atrial fibrillation*1Abstracted from: Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Circulation 2004; 109: 997-1003.

https://doi.org/10.1016/s1361-2611(04)00130-7

Copy DOI

Journal: Evidence-based Cardiovascular Medicine

Publication Date: Sep 1, 2004

#Cardioversion Of Nonvalvular Atrial Fibrillation #Complications In Cardioversion + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Trial finds that enoxaparin may be the preferred drug for initiating anticoagulation in atrial fibrillation*1Abstracted from: Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Circulation 2004; 109: 997-1003.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Evidence-based Cardiovascular Medicine

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.